Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$5.54 USD

5.54
207,804

+0.02 (0.36%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.55 +0.01 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Inovio (INO) Up 14.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

by Zacks Equity Research

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Merck's Ebola Vaccine Gets Conditional Approval in Europe

by Zacks Equity Research

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

by Zacks Equity Research

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inovio (INO) Down More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

by Zacks Equity Research

Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.

Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -7.14% and -97.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

by Zacks Equity Research

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

by Zacks Equity Research

Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

Inovio Up on Enrollment Closure in Cervical Dysplasia Study

by Zacks Equity Research

Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.

Inovio (INO) Down 36.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN Partners Inovio to Develop Companion Diagnostics

by Zacks Equity Research

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for AcelRx (ACRX) This Earnings Season?

by Zacks Equity Research

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

What's in Cards for Cumberland (CPIX) This Earnings Season?

by Zacks Equity Research

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

What's in the Cards for Corbus (CRBP) This Earnings Season?

by Zacks Equity Research

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

Protalix (PLX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.